PEAK6 LLC Lowers Stake in Kenvue Inc. $KVUE

PEAK6 LLC lessened its holdings in Kenvue Inc. (NYSE:KVUE) by 88.2% during the fourth quarter, Holdings Channel.com reports. The firm owned 19,154 shares of the company’s stock after selling 142,584 shares during the quarter. PEAK6 LLC’s holdings in Kenvue were worth $330,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in the business. Physician Wealth Advisors Inc. boosted its position in shares of Kenvue by 67.5% in the 4th quarter. Physician Wealth Advisors Inc. now owns 1,533 shares of the company’s stock worth $26,000 after purchasing an additional 618 shares in the last quarter. Elyxium Wealth LLC purchased a new stake in shares of Kenvue in the 4th quarter worth approximately $26,000. MV Capital Management Inc. bought a new position in Kenvue during the 4th quarter valued at approximately $28,000. Reflection Asset Management bought a new position in Kenvue during the 4th quarter valued at approximately $32,000. Finally, SBI Securities Co. Ltd. increased its position in Kenvue by 82.4% during the 4th quarter. SBI Securities Co. Ltd. now owns 2,273 shares of the company’s stock valued at $39,000 after buying an additional 1,027 shares in the last quarter. Institutional investors own 97.64% of the company’s stock.

Analyst Ratings Changes

KVUE has been the topic of several analyst reports. Zacks Research raised Kenvue from a “hold” rating to a “strong-buy” rating in a report on Friday, May 8th. Argus upgraded Kenvue to a “hold” rating in a report on Friday, March 6th. Barclays lowered their price target on Kenvue from $19.00 to $18.00 and set an “equal weight” rating for the company in a research report on Tuesday, April 14th. Weiss Ratings raised Kenvue from a “hold (c-)” rating to a “hold (c)” rating in a research report on Monday. Finally, UBS Group dropped their price target on shares of Kenvue from $19.00 to $18.00 and set a “neutral” rating on the stock in a research note on Tuesday, April 7th. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and twelve have given a Hold rating to the company’s stock. Based on data from MarketBeat, Kenvue presently has a consensus rating of “Hold” and a consensus price target of $19.33.

Insider Activity

In other news, General Counsel Matthew Orlando sold 38,491 shares of Kenvue stock in a transaction that occurred on Friday, May 8th. The shares were sold at an average price of $17.66, for a total value of $679,751.06. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 1.59% of the stock is currently owned by insiders.

Kenvue Stock Performance

Shares of KVUE opened at $18.17 on Friday. The company has a market cap of $34.88 billion, a price-to-earnings ratio of 21.37, a P/E/G ratio of 1.37 and a beta of 0.54. The business’s fifty day simple moving average is $17.54 and its two-hundred day simple moving average is $17.57. Kenvue Inc. has a 12 month low of $14.02 and a 12 month high of $22.87. The company has a current ratio of 0.98, a quick ratio of 0.70 and a debt-to-equity ratio of 0.67.

Kenvue (NYSE:KVUE) last posted its quarterly earnings results on Thursday, May 7th. The company reported $0.32 earnings per share for the quarter, topping the consensus estimate of $0.27 by $0.05. The firm had revenue of $3.91 billion during the quarter, compared to analysts’ expectations of $3.84 billion. Kenvue had a return on equity of 20.81% and a net margin of 10.61%.The company’s revenue was up 4.5% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.24 earnings per share. Research analysts anticipate that Kenvue Inc. will post 1.16 earnings per share for the current fiscal year.

Kenvue Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Wednesday, May 27th. Stockholders of record on Wednesday, May 13th were issued a dividend of $0.2075 per share. This represents a $0.83 dividend on an annualized basis and a dividend yield of 4.6%. The ex-dividend date of this dividend was Wednesday, May 13th. Kenvue’s dividend payout ratio (DPR) is presently 97.65%.

Kenvue Profile

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.